TY - JOUR
T1 - The contribution of multiparametric pelvic and whole-body MRI to interpretation of 18F-fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure after radical prostatectomy
AU - Metser, Ur
AU - Chua, Sue
AU - Ho, Bao
AU - Punwani, Shonit
AU - Johnston, Edward
AU - Pouliot, Frederic
AU - Tau, Noam
AU - Hawsawy, Asmaa
AU - Anconina, Reut
AU - Bauman, Glenn
AU - Hicks, Rodney J.
AU - Weickhardt, Andrew
AU - Davis, Ian D.
AU - Pond, Greg
AU - Scott, Andrew M.
AU - Tunariu, Nina
AU - Sidhu, Harbir
AU - Emmett, Louise
N1 - Funding Information:
Ian Davis is supported by an Australian National Health and Medical Research Council Practitioner Fellowship (APP1102604), as is Rodney Hicks (APP1108050). The work of Edward Johnston and Shonit Punwani is supported by the UCL/UCLH Biomedical Research Centre. Funding was provided by a GAP2 Collaborative Project Funding Award from the Movember Foundation. No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
COPYRIGHT © 2019 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Our purpose was to assess whether the addition of data from multiparametric pelvic MRI (mpMR) and whole-body MRI (wbMR) to the interpretation of 18F-fluoromethylcholine (18F-FCH) or 68Ga-HBED-CC PSMA-11 (68Ga-PSMA) PET/CT (5PET) improves the detection of local tumor recurrence or of nodal and distant metastases in patients after radical prostatectomy with biochemical failure. Methods: The current analysis was performed as part of a prospective, multicenter trial on 18F-FCH or 68Ga-PSMA PET, mpMR, and wbMR. Eligible men had an elevated level of prostate-specific antigen (PSA) (.0.2 ng/mL) and high-risk features (Gleason score . 7, PSA doubling time, 10 mo, or PSA . 1.0 ng/mL) with negative or equivocal conventional imaging results. PET was interpreted with mpMR and wbMR in consensus by 2 radiologists and compared with prospective interpretation of PET or MRI alone. Performance measures of each modality (PET, MRI, and PET/mpMR-wbMR) were compared for each radiotracer and each individual patient (for 18F-FCH, or 68Ga-PSMA for patients who had 68Ga-PSMA PET) and to a composite reference standard. Results: There were 86 patients with PET (18F-FCH [n 5 76] and/or 68Ga-PSMA [n 5 26]) who had mpMR and wbMR. Local tumor recurrence was detected in 20 of 76 (26.3%) on 18F-FCH PET/ mpMR, versus 11 of 76 (14.5%) on 18F-FCH PET (P 5 0.039), and in 11 of 26 (42.3%) on 68Ga-PSMA PET/mpMR, versus 6 of 26 (23.1%) on 68Ga-PSMA PET (P 5 0.074). Per patient, PET/ mpMR was more often positive for local tumor recurrence than PET (P 5 0.039) or mpMR (P 5 0.019). There were 20 of 86 patients (23.3%) with regional nodal metastases on both PET/wbMR and PET (P 5 1.0) but only 12 of 86 (14%) on wbMR (P 5 0.061). Similarly, there were more nonregional metastases detected on PET/wbMR than on PET (P 5 0.683) or wbMR (P 5 0.074), but these differences did not reach significance. Compared with the composite reference standard for the detection of disease beyond the prostatic fossa, PET/wbMR, PET, and wbMR had sensitivity of 50%, 50%, and 8.3%, respectively, and specificity of 97.1%, 97.1%, and 94.1%, respectively. Conclusion: Interpretation of PET/mpMR resulted in a higher detection rate for local tumor recurrence in the prostatic bed in men with biochemical failure after radical prostatectomy. However, the addition of wbMR to 18F-FCH or 68Ga-PSMA PET did not improve detection of regional or distant metastases.
AB - Our purpose was to assess whether the addition of data from multiparametric pelvic MRI (mpMR) and whole-body MRI (wbMR) to the interpretation of 18F-fluoromethylcholine (18F-FCH) or 68Ga-HBED-CC PSMA-11 (68Ga-PSMA) PET/CT (5PET) improves the detection of local tumor recurrence or of nodal and distant metastases in patients after radical prostatectomy with biochemical failure. Methods: The current analysis was performed as part of a prospective, multicenter trial on 18F-FCH or 68Ga-PSMA PET, mpMR, and wbMR. Eligible men had an elevated level of prostate-specific antigen (PSA) (.0.2 ng/mL) and high-risk features (Gleason score . 7, PSA doubling time, 10 mo, or PSA . 1.0 ng/mL) with negative or equivocal conventional imaging results. PET was interpreted with mpMR and wbMR in consensus by 2 radiologists and compared with prospective interpretation of PET or MRI alone. Performance measures of each modality (PET, MRI, and PET/mpMR-wbMR) were compared for each radiotracer and each individual patient (for 18F-FCH, or 68Ga-PSMA for patients who had 68Ga-PSMA PET) and to a composite reference standard. Results: There were 86 patients with PET (18F-FCH [n 5 76] and/or 68Ga-PSMA [n 5 26]) who had mpMR and wbMR. Local tumor recurrence was detected in 20 of 76 (26.3%) on 18F-FCH PET/ mpMR, versus 11 of 76 (14.5%) on 18F-FCH PET (P 5 0.039), and in 11 of 26 (42.3%) on 68Ga-PSMA PET/mpMR, versus 6 of 26 (23.1%) on 68Ga-PSMA PET (P 5 0.074). Per patient, PET/ mpMR was more often positive for local tumor recurrence than PET (P 5 0.039) or mpMR (P 5 0.019). There were 20 of 86 patients (23.3%) with regional nodal metastases on both PET/wbMR and PET (P 5 1.0) but only 12 of 86 (14%) on wbMR (P 5 0.061). Similarly, there were more nonregional metastases detected on PET/wbMR than on PET (P 5 0.683) or wbMR (P 5 0.074), but these differences did not reach significance. Compared with the composite reference standard for the detection of disease beyond the prostatic fossa, PET/wbMR, PET, and wbMR had sensitivity of 50%, 50%, and 8.3%, respectively, and specificity of 97.1%, 97.1%, and 94.1%, respectively. Conclusion: Interpretation of PET/mpMR resulted in a higher detection rate for local tumor recurrence in the prostatic bed in men with biochemical failure after radical prostatectomy. However, the addition of wbMR to 18F-FCH or 68Ga-PSMA PET did not improve detection of regional or distant metastases.
KW - Biochemical recurrence
KW - Fluoromethylcholine
KW - MR
KW - PET
KW - PSMA
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85071782692&partnerID=8YFLogxK
U2 - 10.2967/jnumed.118.225185
DO - 10.2967/jnumed.118.225185
M3 - Article
C2 - 30902875
AN - SCOPUS:85071782692
SN - 0161-5505
VL - 60
SP - 1253
EP - 1258
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 9
ER -